By Natalie Grover and Maggie Fick LONDON (Reuters) -HSBC’s rescue of the British arm of Silicon Valley Bank saved the heavily-exposed UK biotech sector from collapse, but the fallout could hampe[...]
Read more
Health
Pfizer looks past COVID with $43 billion deal for cancer drug maker Seagen
By Manas Mishra and Michael Erman (Reuters) -Pfizer Inc on Monday struck a $43 billion deal to acquire Seagen Inc and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and[...]
Read more
Activist investor Icahn launches proxy fight at Illumina
(Reuters) – Activist investor Carl Icahn on Monday launched a proxy fight at Illumina Inc, saying the life sciences company’s takeover of Grail Inc had cost shareholders about $50 billion[...]
Read more
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON (Reuters) – The blood thinner Eliquis from Bristol Myers Squibb, Pfizer’s breast cancer drug Ibrance and AbbVie[...]
Read more
Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal
By Ludwig Burger and Dina Kartit (Reuters) -France’s Sanofi SA on Monday agreed to acquire Provention Bio Inc <PRVB.O> for $2.9 billion to bolster its work on a U.S.-approved type 1 diabet[...]
Read more
Novartis initiates new trading line for share buybacks
By Ludwig Burger (Reuters) -Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchase[...]
Read more
Yellen defends request for $29 billion increase in IRS enforcement funds
By David Lawder WASHINGTON (Reuters) – U.S. Treasury Secretary Janet Yellen on Friday defended a Biden administration budget request for an additional $29.1 billion in IRS enforcement funds as R[...]
Read more
Bayer plans to spend $1 billion on US pharma R&D in 2023-US pharma head
By Michael Erman and Patrick Wingrove NEW YORK (Reuters) – Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the countr[...]
Read more
Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine
(Reuters) -Opko Health Inc said on Wednesday it signed a deal with Merck & Co Inc potentially worth up to $922.5 million for its experimental Epstein-Barr virus vaccine. Shares of Opko rose as muc[...]
Read more